Largest ever Parkinson’s research trial is starting now
Date
News
Date
The AI examined images of brain cells and was able to identify changes in key areas of the cell that are characteristic of the different known mechanisms that cause Parkinson’s.
Date
Updated trial results show NLX-112 could treat motor symptoms as well as dyskinesia. If further trials are successful, we could have a valuable new Parkinson’s drug by 2030.
Date
Results from a UK phase 2 clinical trial show that ursodeoxycholic acid (UDCA) is safe for people with Parkinson's and can increase energy production in cells in the brain.
Date
More research needed to investigate the impact of pesticides on brain cells in Parkinson’s
Date
Development of new Parkinson’s treatments is only possible if everyone is part of the research process. We need your help to push promising research forward.
Date
Latest study results show a new test could help diagnose Parkinson’s before damage occurs to brain cells.
Date
Results from a study of a technique known as focused ultrasound have shown a benefit for people with Parkinson’s with movement problems, for up to a year after treatment.
Date
An early phase clinical trial, funded by our supporters through the Parkinson's Virtual Biotech, suggests that the drug NLX-112 is safe and effective for people with Parkinson’s with levodopa-induced dyskinesias.
Date
Researchers compared results from over 150 studies to understand how different types of physical activity can be used to manage Parkinson’s symptoms.
Date
Research into how the brain works, and what happens when things go wrong, is vital to help us find better treatments for Parkinson’s.